These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30190140)

  • 21. Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.
    Whang YE; Hayes DN
    JAMA Oncol; 2015 Jul; 1(4):541. PubMed ID: 26181266
    [No Abstract]   [Full Text] [Related]  

  • 22. [Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor].
    Kaufmann O; Fietze E; Dietel M
    Pathologe; 2002 May; 23(3):183-97. PubMed ID: 12089786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer diagnostics: The journey from histomorphology to molecular profiling.
    Ahmed AA; Abedalthagafi M
    Oncotarget; 2016 Sep; 7(36):58696-58708. PubMed ID: 27509178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
    Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
    Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
    Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
    Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
    Bellizzi AM
    Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer of unknown primary site: improved patient management with molecular and immunohistochemical diagnosis.
    Greco FA
    Am Soc Clin Oncol Educ Book; 2013; ():175-81. PubMed ID: 23714493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site.
    Kandalaft PL; Gown AM
    Arch Pathol Lab Med; 2016 Jun; 140(6):508-23. PubMed ID: 26457625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphology and more specific immunohistochemical stains are fundamental prerequisites in detection of unknown primary cancer.
    Rossi G; Nannini N; Costantini M
    J Clin Oncol; 2009 Feb; 27(4):649-50; author reply 650-2. PubMed ID: 19114684
    [No Abstract]   [Full Text] [Related]  

  • 32. Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site.
    Centeno BA; Bloom G; Chen DT; Chen Z; Gruidl M; Nasir A; Yeatman TY
    J Mol Diagn; 2010 Jul; 12(4):476-86. PubMed ID: 20558571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unknown primary tumors.
    Natoli C; Ramazzotti V; Nappi O; Giacomini P; Palmeri S; Salvatore M; Landriscina M; Zilli M; Natali PG; Tinari N; Iacobelli S
    Biochim Biophys Acta; 2011 Aug; 1816(1):13-24. PubMed ID: 21371531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
    Le Tourneau C; Kamal M; Tsimberidou AM; Bedard P; Pierron G; Callens C; Rouleau E; Vincent-Salomon A; Servant N; Alt M; Rouzier R; Paoletti X; Delattre O; Bièche I
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of Immunohistochemistry in Undifferentiated Neoplasms: A Practical Approach.
    Kandukuri SR; Lin F; Gui L; Gong Y; Fan F; Chen L; Cai G; Liu H
    Arch Pathol Lab Med; 2017 Aug; 141(8):1014-1032. PubMed ID: 28745568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry.
    Conner JR; Hornick JL
    Adv Anat Pathol; 2015 May; 22(3):149-67. PubMed ID: 25844674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.
    Moran S; Martinez-Cardús A; Boussios S; Esteller M
    Nat Rev Clin Oncol; 2017 Nov; 14(11):682-694. PubMed ID: 28675165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cancer: three eras of personalized medicine].
    Jordan B
    Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of Sox10 labeling in metastatic breast carcinomas.
    Nelson ER; Sharma R; Argani P; Cimino-Mathews A
    Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.